BioWorld MedTech

Sep. 6, 2016

After selling med-tech arm, Toshiba plans next-gen radiation therapy

TOKYO – Toshiba Corp. is developing a treatment for cancer that uses particle beams and will send the technology to trial next year, aiming to have a device on the market by the early 2020s. Read More

Senators make a push for incorporation of unique device identifiers into insurance claims forms

FDA hits Tosoh with third warning for U.S. operations since 2005

Ultrasound mobility device for the blind generating good vibrations in Canada

Other news to note

Appointments and advancements

Daily M&A

Financings

MDD's Cardiology Extra

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 10, 2025

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...